Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03419403 · ClinicalTrials.gov registry record · Phase 3
UNITE Study: Understanding New Interventions With GBM ThErapy
A Phase 3 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT03419403 is a Phase 3 study that was terminated before completion, run by AbbVie. The registered enrollment target is 40 participants.
The verdict
NCT03419403, a Phase 3 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated with depatuxizumab mafodotin (ABT-414).
Interventions
- DRUG Depatuxizumab mafodotin
- DRUG Steroid eye drops
- DRUG Vasoconstrictor eye drops
- OTHER Cold compress
- DRUG Ophthalmic steroid ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2020-03-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03419403
The ClinicalTrials.gov registry entry for NCT03419403 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Depatuxizumab mafodotin is the first listed.
NCT03419403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03419403 about?
NCT03419403 is a clinical study titled "UNITE Study: Understanding New Interventions With GBM ThErapy". The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated with depatuxizumab mafo...
What is the current status of trial NCT03419403?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2018-07-30. Estimated completion is 2020-03-03.
What interventions are being tested in trial NCT03419403?
The interventions under investigation include: Depatuxizumab mafodotin (DRUG), Steroid eye drops (DRUG), Vasoconstrictor eye drops (DRUG), Cold compress (OTHER), Ophthalmic steroid ointment (DRUG).
Who is sponsoring clinical trial NCT03419403?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.